Last edition
News about
PharmaForceIQ Strengthens AI Capabilities with Aktana Acquisition
PharmaForceIQ, an end-to-end, real-time customer engagement platform for the pharmaceutical industry, has announced the acquisition of Aktana, integrating its digital commercialization platform with Aktana’s artificial intelligence-driven field next-best-action (NBA) technology.
Merck Explores USD 28-32 Billion Buyout of Oncology Biotech Revolution Medicines
Merck & Co. is in discussions to acquire U.S.-based oncology biotech Revolution Medicines in a deal that could value the company between USD 28 billion and USD 32 billion, according to people familiar with the matter.
Inizio Unveils AI-Enabled Advisory Platform Inizio Ignite to Accelerate Pharma Performance
Inizio, a leading global commercialization partner for pharmaceutical and life sciences, unveiled Inizio Ignite, a reimagined and fully integrated advisory partner designed to accelerate pharmaceutical performance through strategy, insights, and innovation.
Granules Pharmaceuticals Secures US FDA Tentative Approval for gDYANAVEL XR
The tentative approval clears a key regulatory milestone for Granules Pharmaceuticals’ Abbreviated New Drug Application (ANDA), which the US FDA has determined to be eligible for 180-day market exclusivity.
Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial
Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.
PAI Pharma, Olympus Partners Acquire Nivagen to Expand US Sterile Injectable Manufacturing
Deal strengthens domestic pharmaceutical production with advanced aseptic facility and robust ready-to-use injectable pipeline.
Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration
The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.
MediLink, Roche Sign Global Licensing Deal for YL201 ADC Therapy
Agreement includes USD 570 million upfront and milestones to advance B7H3-targeting solid tumor cancer treatment worldwide.
Mercy Joins REACH Study to Evaluate GRAIL Galleri Test in Medicare Population
The three year clinical study will assess real-world impact of multi-cancer early detection testing among up to 50,000 Medicare beneficiaries.
Variant Bio Launches World's First Agentic AI Genomic Drug Discovery Platform
The agentic AI platform by Variant Bio, named Inference, brings together genetic and multi-omic data with autonomous analysis capabilities, and is already powering pharmaceutical partnerships totaling over USD 200 million.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy